We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Study Provides Insights into How Absent Reoviruses Kill Cancer

By LabMedica International staff writers
Posted on 02 Mar 2011
Reoviruses are effectively being used in clinical trials to treat patients with cancer.

Not only does the virus cause cancer cells to die, it also forces them to release proinflammatory chemokines and cytokines, which then causes the patient's immune system to fight the disease. More...
New research has also revealed that reovirus infected cancer cells secrete proteins that, even when isolated, result in the death of cancer cells.

Normal human cells are protected from reovirus infection by a protein called PKR. However, a cellular signaling protein (Ras), which can block PKR activity, is abnormally triggered in many types of cancer, and it provides a window of opportunity for reovirus infection. A multicenter study, involving laboratories in the United Kingdom and the United States, gathered growth media from reovirus infected melanoma cells. The researchers showed that this media contained a range of small proinflammatory proteins, including an interleukin (IL-8) and type 1 interferon (INF-β), which recruited and activated white blood cells, specifically natural killer (NK) cells, dendritic cells (DCs), and antimelanoma cytotoxic T cells (CTLs).

While the precise details behind this mode of action of cell signaling in response to viral infection are unclear, the release of cytokines was dependent on both "inactive" PKR and a specific nuclear factor (NF-κβ). According to Prof. Alan Melcher, from the Leeds Institute of Molecular Medicine (UK), and one of the investigators of the study, "bystander immune-mediated therapy may well be an important component in the treatment of cancer by reoviruses, and may have potential in treating cancer even in the absence of live virus."

The study's findings were published February 20, 2011, by BioMed Central's open access journal Molecular Cancer.

Related Links:
Leeds Institute of Molecular Medicine




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Platelet Function Analyzer
PL-12
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.